23 Jan 2026
Cipla and ImmunoACT launch CAR‑T therapy in Africa
By Staff Writer
Cipla, a global pharmaceutical leader, has partnered with ImmunoACT to introduce talicabtagene autoleucel in Africa. This is India’s first indigenously developed anti‑CD19 CAR‑T therapy. The exclusive license and supply agreement will see Cipla, through its subsidiary Medpro Pharmaceutica, commercialise the therapy in the Republic of South Africa, Algeria and Morocco. Furthermore, ImmunoACT will handle manufacturing....